Neuren Pharmaceuticals Ltd has released a press release.
Appendix 4E and 2023 full year accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- DAYBUE net sales US$87.1 million in Q4 2023
- Comment on research report
- Q4 2023 Appendix 4C Cash Flow Report
- Q4 2023 quarterly activity report
- Completion of enrolment in Neuren's Angelman P2 trial
Later from Neuren Pharmaceuticals
- Neuren reports profit of $157 million for 2023
- Trofinetide accepted for Priority Review by Health Canada
- Q1 2024 quarterly activity and cash flow report
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
- Phase 2 trial shows significant improvements in Pitt Hopkins
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals